collagen degradation

Collagen degradation is a tightly regulated, multi-step biological process wherein collagen fibers—major components of the extracellular matrix—are broken down by specific proteolytic enzymes, mainly matrix metalloproteinases (such as MMP-1, MMP-13, and MMP-14/MT1-MMP) and cathepsins (such as cathepsin K), as well as by intracellular lysosomal enzymes following endocytic uptake of collagen fragments by specialized receptors (e.g., uPARAP/Endo180, integrins). This process is essential for physiological functions like tissue remodeling, wound repair, bone homeostasis, angiogenesis, and cell migration, but dysregulated collagen degradation can contribute to pathological conditions including fibrosis, cancer invasion, osteoporosis, and chronic inflammatory diseases. Because the term refers to a process rather than a single druggable entity, it is more accurate to refer to individual collagenolytic enzymes (for example, matrix metalloproteinase-1 or cathepsin K) as therapeutic targets within this pathway. In summary, "collagen degradation" as written is not a molecular target but a biological process involving multiple recognized drug targets. For structured data, canonical target entries should refer to individual enzymes or receptors mediating collagen breakdown (e.g., "Matrix metalloproteinase-14 (MT1-MMP)", "Cathepsin K").

Other names

Collagenolysis

For MMP inhibitors: Block active site to prevent collagen breakdown. For cathepsin K inhibitors: Inhibit proteolytic activity in bone resorption. Collagen-binding domain drugs: Compete for binding sites to block degradation or deliver therapeutics.